Previous 10 | Next 10 |
2023-10-30 18:01:49 ET Summary Boston Scientific Corporation delivered strong third quarter results, including double-digit organic revenue growth, but the results weren't much better than the Street already expected. The recent clinical data on the Agent DCB and the acquisition o...
2023-10-26 17:21:03 ET Summary Third quarter results from Edwards Lifesciences don't really add much to the bull or bear case, with a small miss (but double-digit growth) in TAVR, and guidance for double-digit growth. Recent presentations from the annual TCT meeting may not look g...
2023-10-26 13:47:07 ET Boston Scientific Corporation (BSX) Q3 2023 Earnings Conference Call October 26, 2023, 8:00 a.m. ET Company Participants Mike Mahoney - Chairman & CEO Dan Brennan - EVP & CFO Dr. Ken Stein - SVP & Global CMO Lauren Tengler -...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
2023-10-26 06:34:55 ET More on Boston Scientific ADVENT Offers Up An Early Present For Boston Scientific Investors Boston Scientific Q3 2023 Earnings Preview Boston Sci, Stryker, Dexcom, Shockwave are BoA's top medtech picks Seeking Alpha’s Quant Ratin...
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023 PR Newswire MARLBOROUGH, Mass. , Oct. 26, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 perce...
Boston Scientific Corporation (BSX) is expected to report $0.48 for Q3 2023
Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial PR Newswire Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB ...
2023-10-25 14:01:10 ET More on Boston Scientific ADVENT Offers Up An Early Present For Boston Scientific Investors Boston Sci, Stryker, Dexcom, Shockwave are BoA's top medtech picks Boston Scientific CEO sells stock worth about $5.9M - filing Seeking Alpha...
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism PR Newswire Analysis is first to compare health system-based electronic heal...
News, Short Squeeze, Breakout and More Instantly...
Boston Scientific Corporation Company Name:
BSX Stock Symbol:
NYSE Market:
Boston Scientific Corporation Website:
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Boston Scientific Announces Results for Second Quarter 2024 PR Newswire MARLBOROUGH, Mass. , July 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.120 billion during the second quarter of 2024, growing 14.5 percent ...
Shares of Boston Scientific Corporation (NYSE: BSX) traded at a new 52-week high today and are currently trading at $78.31. So far today, approximately 1.5M shares have been exchanged, as compared to an average 30-day volume of 5.37M shares. Boston Scientific Corporation develops, manufacture...